KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Leases (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 16 years of Leases data on record, last reported at $1.6 billion in Q4 2025.

  • For Q4 2025, Leases rose 2598.96% year-over-year to $1.6 billion; the TTM value through Dec 2025 reached $1.6 billion, up 2598.96%, while the annual FY2025 figure was $1.6 billion, 2598.96% up from the prior year.
  • Leases reached $1.6 billion in Q4 2025 per VRTX's latest filing, down from $1.6 billion in the prior quarter.
  • Across five years, Leases topped out at $1.6 billion in Q3 2025 and bottomed at $57.9 million in Q4 2024.
  • Average Leases over 5 years is $603.3 million, with a median of $326.6 million recorded in 2022.
  • Peak YoY movement for Leases: tumbled 80.28% in 2024, then skyrocketed 2598.96% in 2025.
  • A 5-year view of Leases shows it stood at $400.1 million in 2021, then decreased by 21.14% to $315.5 million in 2022, then dropped by 6.94% to $293.6 million in 2023, then crashed by 80.28% to $57.9 million in 2024, then surged by 2598.96% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Leases were $1.6 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.3 billion in Q2 2025.